On June 12, Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal Circuit today upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s entecavir compound claim of U.S. Patent No. 5,206,244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA). Teva will finalize the launch plans for this product once it receives final approval from the FDA. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is 1.13%. On last trading day company shares ended up $51.70. Analysts mean target price for the company is $57.09. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 2.35%.
ViiV Healthcare has entered into an agreement with Janssen R&D Ireland Ltd., a subsidiary of Johnson & Johnson (NYSE:JNJ), for the development and commercialization of a single tablet combination of ViiV Healthcare’s Tivicay and Johnson & Johnson’s Edurant. Johnson & Johnson (NYSE:JNJ) shares fell -0.08% in last trading session and ended the day on $102.45. Gross Margin is 69.10% and its return on assets is 11.60%. Johnson & Johnson (NYSE:JNJ) quarterly performance is 9.83%.
Merck & Co. Inc (NYSE:MRK)‘s stock had its “buy” rating reiterated by analysts at Bank of America in a research report issued to clients and investors on Thursday. They currently have a $62.00 target price on the stock, down from their previous target price of $65.00. Bank of America’s target price suggests a potential upside of 6.46% from the company’s current price. Merck & Co., Inc. (NYSE:MRK) shares moved down -0.29% in last trading session and was closed at $58.07, while trading in range of $57.73 – $58.38. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 17.81%.
Novartis AG (ADR) (NYSE:NVS) announced the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal disease caused by serogroup B (meningitis B) in adolescents and young adults from 10 years through 25 years of age. Novartis AG (ADR) (NYSE:NVS) ended the last trading day at $90.39. Company weekly volatility is calculated as 0.52% and price to cash ratio as 31.82. Novartis AG (ADR) (NYSE:NVS) showed a positive weekly performance of 1.44%.
On June 12, Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) has a broad portfolio of diagnostic tests with more than a hundred high-quality Elecsys assays for immune testing along with a new generation of fully automated cobas analyzers for improved medical decision making, scheduling and efficiency. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) On last trading day company shares ended up $37.23 .